Informatie:
Fout:
ID
22949
Beschrijving
Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00420927
Link
https://clinicaltrials.gov/show/NCT00420927
Trefwoorden
Versies (1)
- 18-06-17 18-06-17 -
Geüploaded op
18 juni 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Rheumatoid Arthritis NCT00420927
Eligibility Rheumatoid Arthritis NCT00420927
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT00420927
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Age | Overall Well Being
Item
subject must be 18 or older and in good health
boolean
C0001779 (UMLS CUI [1])
C3813622 (UMLS CUI [2])
C3813622 (UMLS CUI [2])
Early Rheumatoid Arthritis disease length
Item
subject must meet the definition of early rheumatoid arthritis (ra) defined by the 1987-revised american college of rheumatology (acr) classification criteria and had disease duration of less than 1 year from diagnosis
boolean
C3899278 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0872146 (UMLS CUI [1,2])
Disease activity score | C-reactive protein measurement | Swollen joint count | Tender joint count
Item
subject must have a disease activity score (das28, based on c-reactive protein) greater than 3.2, at least 6 swollen joints out of the 66 assessed, and at least 8 tender joints out of the 68 assessed
boolean
C2732493 (UMLS CUI [1])
C0201657 (UMLS CUI [2])
C0451521 (UMLS CUI [3])
C0451530 (UMLS CUI [4])
C0201657 (UMLS CUI [2])
C0451521 (UMLS CUI [3])
C0451530 (UMLS CUI [4])
Criteria Fulfill
Item
subject must fulfill at least one of the following three criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,2])
Rheumatoid factor positive
Item
rheumatoid factor positive
boolean
C0151379 (UMLS CUI [1])
Joint erosion Quantity
Item
greater than 1 joint erosion
boolean
C0022417 (UMLS CUI [1,1])
C0587240 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0587240 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Anti-cyclic citrullinated peptide antibody positive
Item
anti-cyclic citrullinated peptide (ccp) antibody positive.
boolean
C2609056 (UMLS CUI [1])
Anti-tumor necrosis factor therapy Systemic
Item
subject has previously received systemic anti-tumor necrosis factor (tnf) therapy
boolean
C0281481 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0205373 (UMLS CUI [1,2])
Biological treatment | Investigational Therapy
Item
subject has received any biologic or investigational therapy within 6 weeks prior to baseline
boolean
C1531518 (UMLS CUI [1])
C0949266 (UMLS CUI [2])
C0949266 (UMLS CUI [2])
Disease-Modifying Antirheumatic Drugs Quantity | Methotrexate | intraarticular injection of corticosteroids | Adrenal Cortex Hormones Parenteral | Operation on joint | Joints Assessment Clinical Trial
Item
subject has been previously treated with more than 2 disease-modifying antirheumatic drugs (dmards) or mtx, had been treated with intra-articular or parenteral administration of corticosteroids in preceding 4 weeks, or had undergone joint surgery within the preceding 2 months at joints to be assessed during the study.
boolean
C0242708 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0025677 (UMLS CUI [2])
C2064783 (UMLS CUI [3])
C0001617 (UMLS CUI [4,1])
C1518896 (UMLS CUI [4,2])
C0185132 (UMLS CUI [5])
C0022417 (UMLS CUI [6,1])
C1516048 (UMLS CUI [6,2])
C0008976 (UMLS CUI [6,3])
C1265611 (UMLS CUI [1,2])
C0025677 (UMLS CUI [2])
C2064783 (UMLS CUI [3])
C0001617 (UMLS CUI [4,1])
C1518896 (UMLS CUI [4,2])
C0185132 (UMLS CUI [5])
C0022417 (UMLS CUI [6,1])
C1516048 (UMLS CUI [6,2])
C0008976 (UMLS CUI [6,3])